A Phase 1 interventional study of Baricitinib and Ketoconazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to look at the effect of ketoconazole and fluconazole on how much baricitinib gets into the blood stream. The study will also look at the tolerability of baricitinib and ketoconazole when given together and the tolerability of baricitinib and fluconazole when given together.
Participants will be recruited into 1 of 2 treatment groups (Group A or Group B). Each treatment group will participate in 2 study periods. Participants will take baricitinib alone in 1 period and baricitinib with either ketoconazole or fluconazole in the other period. This study will last approximately 7 weeks.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2. Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2.
Drug: Baricitinib · Drug: Ketoconazole
Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2. Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2.
Drug: Baricitinib · Drug: Fluconazole
Administered orally
Also known as: LY3009104
Administered orally
Administered orally
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
PK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
PK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
PK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
PK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
| Milestone | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) |
|---|---|---|
| Started | 18 | 18 |
| Received baricitinib | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
| Milestone | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) |
|---|---|---|
| Started | 18 | 18 |
| Received at least 1 dose of study drug | 18 | 18 |
| Received baricitinib | 17 | 17 |
| Completed | 17 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| nanograms*hour/milliliter (ng*h/mL) | Baricitinib (Group A) | Baricitinib + Ketoconazole (Group A) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole | 720 ± 23 | 868 ± 24 |
| ng*h/mL | Baricitinib (Group B) | Baricitinib + Fluconazole (Group B) |
|---|---|---|
| PK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole | 698 ± 24 | 851 ± 24 |
| nanograms/milliliter (ng/mL) | Baricitinib (Group A) | Baricitinib + Ketoconazole (Group A) |
|---|---|---|
| PK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole | 106 ± 27 | 115 ± 32 |
| ng/mL | Baricitinib (Group B) | Baricitinib + Fluconazole (Group B) |
|---|---|---|
| PK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole | 103 ± 36 | 107 ± 38 |
| hours | Baricitinib (Group A) | Baricitinib + Ketoconazole (Group A) |
|---|---|---|
| PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 2.00) |
| hours | Baricitinib (Group B) | Baricitinib + Fluconazole (Group B) |
|---|---|---|
| PK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole | 1.00 (0.50 to 4.00) | 1.00 (0.50 to 3.00) |
Collected over Baseline through study completion (up to Day 23).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baricitinib (Group A) | — | 0/18 (0%) | 4/18 (22.2%) |
| Ketoconazole (Group A) | — | 0/18 (0%) | 7/18 (38.9%) |
| Baricitinib + Ketoconazole (Group A) | — | 0/17 (0%) | 4/17 (23.5%) |
| Baricitinib (Group B) | — | 0/18 (0%) | 3/18 (16.7%) |
| Fluconazole (Group B) | — | 0/18 (0%) | 4/18 (22.2%) |
| Baricitinib + Fluconazole (Group B) | — | 0/17 (0%) | 6/17 (35.3%) |
| Event | Baricitinib (Group A) | Ketoconazole (Group A) | Baricitinib + Ketoconazole (Group A) | Baricitinib (Group B) | Fluconazole (Group B) | Baricitinib + Fluconazole (Group B) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/18 | 6/18 | 2/17 | 1/18 | 0/18 | 1/17 |
| NauseaGastrointestinal disorders | 0/18 | 0/18 | 0/17 | 0/18 | 2/18 | 0/17 |
| Catheter site related reactionGeneral disorders | 0/18 | 0/18 | 1/17 | 0/18 | 0/18 | 1/17 |
| Influenza like illnessGeneral disorders | 0/18 | 0/18 | 0/17 | 0/18 | 0/18 | 1/17 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 0/18 | 0/17 | 0/18 | 0/18 | 1/17 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/18 | 0/18 | 0/17 | 0/18 | 1/18 | 1/17 |
| Neck painMusculoskeletal and connective tissue disorders | 0/18 | 0/18 | 1/17 | 0/18 | 0/18 | 0/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 0/17 | 0/18 | 0/18 | 1/17 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 0/17 | 0/18 | 0/18 | 1/17 |
| ErythemaSkin and subcutaneous tissue disorders | 0/18 | 0/18 | 1/17 | 0/18 | 0/18 | 0/17 |
All enrolled participants.
| Age, Continuous(years) | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) | Total |
|---|---|---|---|
| Mean | 42.3 ± 15.0 | 42.7 ± 13.7 | 42.5 ± 14.2 |
| Sex: Female, Male(Participants) | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) | Total |
|---|---|---|---|
| Female | 2 | 6 | 8 |
| Male | 16 | 12 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 18 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 16 | 16 | 32 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Baricitinib + Ketoconazole (Group A) | Baricitinib + Fluconazole (Group B) | Total |
|---|---|---|---|
| United Kingdom | 18 | 18 | 36 |
The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib